blindness from tirzepatide reduces food intake and appetite, and affects brain functioning, more than placebo and liraglutide Ozempic and vision loss: GLP-1

In 2024, it was also approved to reduce the risk of serious heart issues in adults with heart disease and excess weight

Clinical , vol

Lilly later pursued a separate approval for chronic weight management and obtained FDA approval for Zepbound in 2023

They may be considered as part of dual or triple therapy when specific criteria are met, including BMI thresholds (35 kg/m or 32.5 kg/m in certain ethnic groups) and when weight loss would benefit other obesity-related comorbidities

While more research is needed, the study suggests that there may be some risks in addition to benefits of using GLP-1s in people with breast cancer and obesity who are taking hormonal therapy

Decisions should be individualized based on the patient's overall health status, diabetes control, and goals of care